Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Inactive
Last updated: April 9, 2025
Lisvy®

FC-Patch Low, Gestodene (GES) + Ethinyl Estradiol (EE) Patch

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Transdermal
  • Intended Duration: Short-Acting
  • Development Stage: Phase IV
  • Developer(s)/Researcher(s): WHO HRP, Bayer HealthCare, Gedeon Richter Plc.
Inactive
Last updated: April 9, 2025
Levonorgestrel Intracervical Device (ICD)
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal - Other
  • Intended Duration: Long-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): University of Helsinki, Population Council
Inactive
Last updated: April 9, 2025
Levogel

Pericoital LNG Gel

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Population Council
Active
Last updated: April 9, 2025
IUB PRIMA

Hormonal Intrauterine Ball

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Intrauterine
  • Intended Duration: Long-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): OCON Medical Ltd.
Active
Last updated: April 9, 2025
Injectable Nanoparticles for Targeted Exogenous Testicular Hyperthermy

Magnetic Testicular Hyperthermy, Near-Infrared Testicular Hyperthermy, Metallic Nanoparticles

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Testicular
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Nantong University
Active
Last updated: April 9, 2025
Injectable LNG in PLA/PLGA Microspheres

LNG Long-Acting Microsphere Injectable (LLMI)

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): FHI 360, Shanghai Institute for Biomedical and Pharmaceutical Technologies
Inactive
Last updated: April 9, 2025
Injectable EE + DRSP PLGA Microcapsules
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Long-Acting
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Bayer
Inactive
Last updated: April 9, 2025
In-Situ Forming Gel (UTHSC)
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Tennessee Health Sciences Center
Active
Last updated: April 9, 2025
GSK3α-Inhibiting Compound

BRD0705

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Kent State University, Broad Institute, Manipal Centre for Biotherapeutics Research
Inactive
Last updated: April 9, 2025
Gamma Irradiated Injectable LNG Microparticles
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Undetermined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Mumbai